Skip to main content
Log in

Bexarotene

A Viewpoint by Alain H. Rook, Michael S. Lehrer, Jacqueline M. Junkins-Hopkins, Carmella C. Vittorio, Lars E. French

  • Adis New Drug Profile
  • Guest Commentaries
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Duvic M., Martin A., Hymes K., et al. Oral bexarotene capsules as treatment for all stages of refractory or persistent CTCL [abstract no. 150]. J Invest Dermatol 2000 114: 776

    Google Scholar 

  2. Smit J., de Jong E., van Hooijdonk C., et al. A multicentre phase II clinical and immunohistochemical trial of systemic bexarotene (Targretin) in psoriasis [abstract no. 151]. J Invest Dermatol 2000, 114: 776

    Google Scholar 

  3. Boehm M.F., Heyman R.A., Patel S., et al. Retinoids: Biological function and use in the treatment of dermatological diseases. Expert Opin Invest Drug 1995, 4: 593–612

    Article  CAS  Google Scholar 

  4. Fox F.E., Kubin M., Cassin M., et al. Retinoids synergize with interleukin-2 to augment interferon gamma and interleukin-12 production by human peripheral blood mononuclear cells. J Interferon Res 1999, 19: 407–415

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rook, A.H., Lehrer, M.S., Junkins-Hopkins, J.M. et al. Bexarotene. Am J Clin Dermatol 1, 251 (2000). https://doi.org/10.2165/00128071-200001040-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200001040-00007

Keywords

Navigation